erythroid cells. These data were combined with gene expression analyses and candidate enhancers identified. Consistent with their predicted function as candidate enhancers, there was statistically significant enrichment of p300 and combinations of co-localizing erythroid transcription factors within 1-50 kb of the TSS of genes highly expressed in erythroid cells. Candidate enhancers were also enriched near genes with known erythroid cell function or phenotype. Candidate enhancers exhibited moderate conservation with mouse and minimal conservation with nonplacental vertebrates. Candidate enhancers were mapped to set of erythroid associated, biologically relevant, SNPs from the GWAS catalog of the NHGRI. Fourteen candidate enhancers, representing 10 genetic loci, mapped to sites associated with biologically relevant erythroid traits. Fragments from these loci directed statistically significant expression in reporter gene assays. Identification of enhancers in human erythroid cells will allow a better understanding of erythroid cell development, differentiation, structure, and function, and provide insights into inherited and acquired hematologic disease.
INTRODUCTION
Erythrocytes are specialized cells that have evolved to efficiently carry out their primary functions of oxygen transport and delivery. Among the vertebrates, mammalian erythrocytes are unique. Mature mammalian erythrocytes are enucleate and lack most cellular organelles. Erythroid progenitor cells contain nuclei, but they are extruded, presumably to allow for additional hemoglobin content for more efficient oxygen transport. Lacking DNA, mature erythrocytes lack the capacity for cell division or RNA synthesis, and they have very limited capacity for self repair. Thus erythroid cells are highly specialized cells with a number of unique characteristics.
The regulation of programs controlling cellular development and differentiation vary temporally, between cell and tissue types, and between species. These programs are controlled by critical regulatory DNA sequences, cis-regulatory modules (CRM), which include gene promoters, enhancers, silencers and insulators. A detailed understanding of the structure and function of CRMs in varying cell types will provide insights into these regulatory programs and provide crucial information for predicting and understanding the phenotypic consequences of genetic variation in noncoding DNA. Recent studies utilizing genomic methodologies have shown that enhancers, a class of CRMs, are frequently associated with diseaseassociated genetic variants. (1) (2) (3) (4) (5) (6) Enhancers have been classified into two groups, those marked by p300, the transcriptional co-activator also frequently found at gene promoters, and those that lack p300, but instead are occupied by cell and tissue-type specific transcription factors. (7) (8) (9) (10) (11) (12) In addition, specific patterns of enhancer-associated chromatin architecture have been described. (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) Enhancers demonstrate tissue, cell and developmental stage specificity. Phylogenetic conservation has been used as an indicator for functional conservation of enhancers throughout evolution; (16, (27) (28) (29) (30) (31) (32) however, varying degrees of sequence conservation between cell types in different species has been observed. In some human tissues, such as forebrain, enhancers are subject to stringent evolutionary constraint, whereas in others, such as heart, they are under weak evolutionary constraint. (12, 16, (33) (34) (35) (36) (37) (38) In some cell and tissue types, structural and functional conservation of enhancer elements is significantly lacking, even between species as close as mouse and human. (34) Mammalian genomes contain more enhancers than promoters, with enhancers subserving numerous roles in controlling gene regulation. (6, 13, 39, 40) Tissue-specific genes are more dependent on enhancer regulation and exhibit less promoter diversity than housekeeping genes, which are primarily regulated by their promoters with few enhancers in their genomic vicinity.(1) Identification and characterization of enhancers that control programs of gene expression in highly specialized human erythroid cells will allow a better understanding of erythroid cell development, differentiation, structure, and function, as well as provide insights into inherited and acquired hematologic disease.
This report describes the construction of genome-wide maps of candidate enhancers in primary human erythroid cells. Genome-wide maps of p300 and four erythroid transcription factors, GATA1, NF-E2, KLF1, and SCL, in human primary erythroid cell chromatin were constructed and analyzed with parallel gene expression analyses. Consistent with their predicted function, these regulatory elements were enriched near genes highly expressed in erythroid cells or involved in erythroid cell structure and function. Conservation analyses of candidate human enhancers revealed only moderate conservation with mouse and minimal conservation with nonplacental vertebrates. Fourteen candidate enhancers, representing 10 genetic loci, mapped to sites previously associated with biologically relevant erythroid cell traits in genome-wide association studies (GWAS). Fragments from 9 of the 10 biologically relevant regions directed statistically significant expression in reporter gene assays.
EXPERIMENTAL PROCEDURES
Cell culture and selection. To obtain primary human erythroid cells, CD34+ cells were cultured and selected as described. (41, 42) These cells represent the R3/R4 cell population of nucleated erythroid cells defined by Zhang et al.(43) RNA isolation and preparation, microarray data acquisition and analyses. RNA was prepared from primary human erythroid cells and prepared for microarray analyses as described (44, 45) and detailed in Supplemental Methods. Gene expression microarray quality control and data analyses are described in Supplemental Methods. Quantitative real-time PCR was performed to confirm expression levels of RNA transcripts with the primers in Supplemental Table S1 . Real-time PCR data were normalized as described. (45) The PhastCons conservation scores of regions surrounding promoters, exons, distal and intergenic regions were compared to the PhastCons scores of randomized regions generated by combining the regions for all transcription factor binding sites and moving the regions to random locations in the genome outside of gaps in the known hg18 sequence using the BedTools ShuffleBed function. Conservation plots were generated using Cistrome.(52) Conservation of human candidate enhancer regions was analyzed using the UCSC LiftOver tool. For LiftOver controls, sites were concatenated, randomly shuffled across the genome and analyzed. The maximum PhastCons score for each candidate enhancer mapped to sites previously associated with biologically relevant erythroid cell traits in GWAS studies was determined using the Galaxy aggregate function. (53, 54) The UCSC genome browser 7X regulatory potential table was used to determine the maximum regulatory potential (RP) scores for each region. (54, 55) Identification and analysis of biologically relevant SNPs. The locations of SNPs shown to demonstrate highly significant linkage to erythroid cell-related traits were obtained from the UCSC genome browser database and the catalog of published Genome-Wide Association Studies (GWAS) compiled by the National Human Genome Research Institute (www.genome.gov/ gwastudies).(4) Using BedTools software (See Supplemental Methods), nonpromoter-related p300 peaks (TSS to +/-1kb) were intersected with erythroid-related SNPs and overlap identified. Similarly, peaks with 2 or more sites of erythroid transcription factor binding identified by Active Region Comparer were intersected with erythroidrelated SNPs.
Validation of ChIP-seq results. Primers were designed for representative binding regions for all five antibodies in target genes identified by the MACS program (Supplemental Table S2 ). Immunoprecipitated DNA was analyzed by quantitative real-time PCR (iCycler, Bio-Rad) as described. (44) Reporter gene assays. Fourteen candidate enhancer regions were PCR-amplified using oligonucleotide primers immediately flanking the boundaries of the called peaks (Supplemental Table S3 ). These fragments were cloned upstream of a SV40 promoter-firefly luciferase reporter cassette in the pGL2Promoter plasmid. Integrity of all test plasmids was confirmed by sequencing. The negative control plasmid contained a promoterless-firefly luciferase gene cassette, PGL2Basic (Promega), and the positive control plasmid contained a -globin gene promoter-firefly luciferase reporter gene cassette with the human beta-globin gene HS2 enhancer cloned upstream of the -globin-luciferase cassette. (56) 10 7 K562 cells (ATCC, CCL 243) were transfected by electroporation with a single pulse of 300V at 950μF with 15μg of test plasmid and 0.3µg of pRL-TK, a reporter plasmid expressing Renilla luciferase driven by the herpes simplex virus thymidine kinase (HSV-TK) promoter (Promega) as described. (57) At least two preparations of each plasmid were tested in triplicate. Two days after transfection, cell extracts were analyzed using the Dual-Luciferase assay according to manufacturer's instructions (Promega). Firefly luciferase activity directed by each of the test plasmids, corrected for the Renilla luciferase activity of the cotransfection control, was normalized by firefly luciferase activity from the pGL2P control plasmid to obtain the fold change. Statistical significance was determined as p<0.01 by the Student's t-test.
Data access. The raw data files generated by the ChIP-seq analyses and microarray assays have been submitted to Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) for use by other investigators. The mRNA microarray experiments comply with MIAME (Minimum Information About a Microarray Experiment) standards. (58) RESULTS mRNA expression and p300 and erythroid transcription factor ChIP-seq analyses in human primary erythroid cells. Human primary erythroid cells, representing the R3/R4 populations of cells, (43) were cultured from human CD34+ stem and progenitor cells. Transcriptome analyses were performed with erythroid cell mRNA hybridized to Illumina human v2 mRNA expression arrays. Levels of expression were assigned absent or present calls using the Illumina detection p-values based on negative control hybridization probes. Of 19,707 transcripts examined, 8678 transcripts were expressed. Quantitative real-time PCR was performed to validate expression levels of representative mRNA transcripts assigned by the expression arrays (Supplemental Table S4 and Supplemental Figure 1) .
Using primary erythroid cell chromatin, ChIP-seq was performed utilizing antibodies specific for the transcriptional co-activator p300 and the erythroid transcription factors GATA1, NF-E2, KLF1, and SCL/Tal1 to generate genomewide maps of factor binding. Genome-wide maps of H3K4me2 and H3K4me3 occupancy were similarly constructed. The MACS program was used to identify peaks with a cutoff of pvalue<10e-5 (Supplemental Table S5 ). Validation of factor enrichment at selected peaks identified by ChIP-seq was performed by quantitative ChIP PCR for all 5 antibodies (Supplemental Table S6 ).
Sites of p300 and erythroid transcription factor occupancy in erythroid cell chromatin. The human genome was portioned into six bins relative to RefSeq genes corresponding to exons, introns, promoters, distal (-1 to -50kb), downstream (+1to +50kb), and intergenic regions. Sites of factor occupancy were assigned to these bins and percentages calculated (Figure 1 ). p300 and erythroid transcription factors were enriched in introns and distal regions (1-50 kb from a RefSeq gene) (Figure 1 ). p300 occupancy was also enriched in promoters and exons, consistent with the alternate role of p300 as a transcriptional coactivator at gene promoters. Sites of erythroid transcription factor binding were also enriched in intergenic regions (>50kb from a RefSeq gene; 17-18%) (Figure 1 ). Like previous reports, erythroid transcription factor binding was very common in intron 1 of RefSeq genes (Data not shown.). (44, 59 ) These data suggest that transcription factors mark enhancers more commonly than p300 in erythroid cells, as bona fide enhancers are expected to act in the genomic vicinity of their cognate genes. (35) Co-localization of p300 and erythroid transcription factors. The co-localization of p300 and erythroid cell transcription factors was analyzed using Active Region Comparer. Erythroid transcription factors commonly colocalized, especially the combinations of KLF1 and NF-E2, GATA1 and KLF1, and GATA1 and NF-E2 (Table 1) . Interestingly, three or more erythroid transcription factors co-localized frequently, ~17% of the time. Co-localization of p300 with individual erythroid transcription factors was less frequent (Table 1 ). These data indicate that like other cell types studies, candidate erythroid cell enhancers are typically identified by p300 occupancy or co-localization of tissueexpressed transcription factors. (60, 61) The Homer program was utilized to identify over-represented DNA motifs at sites of factor binding. Not surprisingly, related motifs were found among the erythroid transcription factors, e.g. GATA1 with PU.1, KLF1 with GATA1, NF-E2 with GATA1, and SCL with GATA1. These results are shown in Supplemental Figure 2 .
Identification of candidate erythroid enhancer regions. Genomic studies have identified two classes of enhancers, those marked by p300 binding and those marked by binding of multiple cell and tissue-type specific transcription factors. We defined candidate erythroid enhancers as regions of DNA marked by nonpromoterassociated p300 occupancy or nonpromoter binding of two or more erythroid transcription factors. Typically, cell and tissue-type specific enhancers act over distances of tens to hundreds of kilobases.(34) Thus bona fide erythroid enhancers are expected to be enriched in the genomic vicinity of genes that are expressed and functional in erythroid cells. (1, 13, 62) To determine whether erythroid enhancers are localized in this manner, gene expression in erythroid cells was correlated with sites of occupancy of p300 and erythroid transcription factors. To exclude gene promoters, localization of p300 or erythroid transcription factors within 1kb of annotated transcriptional start sites (TSS) was excluded from the analyses. There was a statistically significant higher erythroid expression of genes with p300 binding sites within 1-50 kb of the TSS compared to expression of genes with p300 binding sites >50kb of a TSS (Figure 2, p-value<2.2e-16 ; Supplemental Table S7 ). Similar to p300, there was statistically significant higher expression of genes with erythroid transcription factor binding sites within 1-50 kb of the TSS compared to expression of genes with binding sites >50kb of a TSS (Figure 2 ). This was true when combinations of two, three, or four co-localizing erythroid transcription factors were analyzed (p-value<2.2e-16 for all 3 combinations, respectively). As expected, (6) H3K4me3 occupancy was uncommonly found at sites of candidate enhancers (Supplemental Table S7 ).
We also examined whether candidate enhancers were enriched near genes with known erythroid cell structure or function. We performed an unsupervised statistical enrichment analysis of functional gene annotations.(63) Candidate erythroid enhancers identified by 2 of 4 erythroid transcription factors were associated with genes linked to erythroid cell-related phenotypes ( Table  2 and Supplemental Table S6 ). Candidate enhancers identified by p300 were not associated with genes linked to erythroid-cell related phenotypes (data not shown). Analyzing genes with candidate enhancers identified by 2 of 4 erythroid transcription factors by Gene Ontology (GO) annotation identified biological processes involved in erythroid cell function including K-Cl cotransporter activity, myosin binding, glucose transport, and cellular iron homeostasis (Supplemental Table S8 ).
To further determine whether candidate enhancers identified by 2 of 4 erythroid transcription factors were associated with genes with erythroid cell function, the number of genes induced during erythroid differentiation associated with candidate enhancers (1-50kb) was compared to the number of genes with randomized candidate enhancers (1-50kb). The number of genes induced during erythroid differentiation was significantly higher than the number of genes from randomized enhancer locations (p-value <0.01).
In addition, candidate enhancers were associated with genes in the GO term categories erythrocyte differentiation and erythrocyte homeostasis (p-values <0.01 and <0.01, respectively) and were not associated with genes in the GO term categories muscle differentiation and neuron differentiation (p-values 0.50 and 0.91, respectively).
Conservation analyses of candidate enhancer regions. Evolutionary constraint in regions of noncoding DNA has served as a proxy for functional constraint in the identification of candidate enhancer regions. However, recent studies have demonstrated that many enhancers are rapidly evolving, and in some species, many enhancers are both evolutionarily young and species-specific. (33, 36) We investigated conservation of candidate erythroid enhancers between man, mouse, chicken, frog and zebrafish at different levels of stringency using the UCSC Genome Browser LiftOver tool, a computational tool that utilizes BLAT algorithm alignments to identify orthologous sequences between species.(47,64) Conservation was analyzed for candidate enhancers located in distal, intergenic, and intron regions, avoiding the high degree of conservation typically found between gene promoters and exons. Even at lower stringency (50% minimum ratio of bases that must remap), there was very high conservation between man and mouse for p300, all four erythroid transcription factors, and the combination of 2 of 4 erythroid transcription factors compared to randomly shuffled control sequences (Table 3) . There was a very large falloff of conservation between human and lower nonmammalian species with nucleated circulating erythrocytes for the erythroid transcription factors, even at low stringency (50% minimum ratio of bases that must remap).
Conservation plots using PhastCons conservation scores with the 44-way vertebrate and placental mammal PhastCons track were constructed for binding regions of p300 and the four erythroid transcription factors. Strong conservation for p300 and all the erythroid transcription factors was present in gene promoters and exons. However, there was weak constraint for p300 and the erythroid transcription factors, with the exception of SCL/Tal1, at distal and intergenic sites (Figure 3) .
Candidate enhancer regions and biologically relevant single nucleotide polymorphisms. We explored whether candidate erythroid enhancers are enriched in regions associated with biologically relevant erythroid cell traits. We collected a data set of erythroidassociated non-coding SNPs (see Methods) from the GWAS catalog of the NHGRI (www.genome.gov/gwastudies).(4) Currently, the functional significance of the overwhelming majority of these SNPs is unknown. SNP locations were compared to the sites of p300 or erythroid transcription factor occupancy. Fourteen SNPs associated with erythroid cell phenotypes were identified (Table 4 and Supplemental Figure S3) , with four of the biologically relevant SNPs located in intron 2 of the BCL11A gene on chromosome 2. p300 occupancy was found at six SNPs, 3 without erythroid transcription factors, and once each with two, three, and four, co-localizing erythroid factors, respectively. Nine of the fourteen SNPs had co-occupancy with the combination of erythroid factors GATA1, NF-E2 and KLF1.
Recent studies have used PhastCons analyses and Regulatory Potential (RP) scores to predict whether or not a region of DNA contains a functional CRM. (54, 59, 65) PhastCons uses a hidden Markov model method on aligned genomic sequences to estimate a probability that any nucleotide is conserved. (66) The UCSC genome browser was used to determine 44-way placental mammal PhastCons scores for each of the 14 candidate biologically relevant enhancer regions. Twelve of 14 enhancer regions had maximal PhastCons scores of >0.8, suggesting that they contain a functional CRM (Table 5 ). An alternative way to predict the presence of CRMs is the RP score, which evaluates whether regions of DNA sequence have patterns more similar to those of regulatory elements or neutral DNA. Positive RP scores (RP scores of >0)(54) indicate conserved regions which contain a functional CRM. All 14 enhancer regions had positive maximal RP scores.
Reporter gene assay of biologically relevant enhancers in erythroid cells. Individual reporter gene plasmids were prepared with the biologically relevant enhancer elements cloned upstream of a human -globin gene promoterluciferase reporter gene cassette. These plasmids were transfected into human K562 cells, which have features of human erythroid cells. After two days, the cells were harvested and luciferase activity analyzed. The luciferase reporter gene was driven by the human -globin gene promoter which is expressed in K562 cells. Activity from test plasmids was normalized to that directed by the human -globin gene promoter-luciferase reporter gene control plasmid. Thirteen of the 14 candidate enhancers mapped to biologically relevant SNPs directed statistically significant (p<0.01) reporter gene activity (Figure 4) . A cluster of 4 of these SNPs, all linked with levels of hemoglobin F, were located in intron 2 of the BCL11A gene. Fragments containing 3 of 4 of these SNPs directed statistically significant reporter gene activity, suggesting the other SNPs required intact chromatin for their function, they were in linkage disequilibrium, they were nonfunctional, or they were associated with other functions.
DISCUSSION
Mammalian erythroid cells are an excellent example of the complexity in temporal, developmental, and differentiation stage specific changes exhibited by a single cell type. Mammalian erythroid cells originate from hematopoietic stem and progenitor cells (HSPCs). In the embryo and fetus, erythroid cells have differing developmental origins, with the primitive erythroid cell lineage developing from yolk sacderived erythroid progenitors, and the definitive cell lineage maturing from two different developmentally-regulated stem and progenitor cell populations.(67-70) These cells have different programs of regulation, with variation in spatial, temporal, and site-specific differentiation. Indeed, altered programs of erythropoiesis are activated throughout the life of the organism, such as occurs after blood loss, oxidative stress, or other organismal stress.
Our conservation analyses revealed that erythroid cell enhancers, like heart enhancers, are under weak evolutionary constraint, particularly when comparing placental mammals and nonplacental vertebrates. They also indicated that many candidate erythroid enhancers are species specific and evolutionarily young. Mammalian erythrocytes are among the most highly specialized cells known, having evolved to an enucleate cell endowed with a highly redundant cell membrane. These changes, which increase surface area and cytoplasmic volume ratios, are primarily attributed to the need for additional hemoglobin content for oxygen transport, making cellular oxygen diffusion more efficient. As homeotherms evolved, oxygen demands increased, and organisms evolved to meet these demands. Birds developed a flow-through respiratory system, significantly more efficient than mammalian respiratory systems. It has been suggested that mammals diverged at this point, developing enucleate erythrocytes with increased oxygen carrying capacity to adapt to increased oxygen demands. (71) (72) (73) (74) Because discrete changes in CRMs may alter gene expression, generating potential for the genesis of novel species-specific traits, (75, 76) identification of gene expression changes occurring over short evolutionary distances can suggest the origin of species-specific traits. Thus comparative studies of enhancers in human and nonplacental vertebrates will likely provide novel information about the evolution of erythrocyte structure and function.
Our understanding of enhancer structure and function continues to expand. Previous studies, such as those of the globin gene loci,(77-81) the GATA1 and SCL/Tal1 gene loci (82) (83) (84) (85) (86) (87) (88) (89) (90) (91) (92) (93) and the erythropoietin gene locus,(83) characterized enhancers as distantly located, positively acting cis-regulatory elements. (77, 80) Recent studies have shown that enhancers have additional, complex roles in cellular gene regulation. These include roles in determining nuclear organization,(6) transcription initiation and release of RNA polymerase II from promoter pausing, (18) (115) Our data demonstrate the role of cell-expressed transcription factors and p300 in marking erythroid cell enhancers, reveal the lack of evolutionary constraint of human erythroid enhancers, and show a significant link of enhancers with human erythroid cell phenotypes. Ongoing synthesis of the data obtained from complementary lines of investigation is beginning to unravel the complex mechanisms of genetic variation in disease susceptibility. (125) Identification of critical cis-regulatory elements in erythroid cells will also be extremely useful in the genetic diagnosis of patients with hematologic disease. In some cases of inherited disease, deleterious coding region mutations have been identified on one allele, but the causative mutation in trans has not been identified. For instance, erythroid cells from a subset of patients with recessively inherited, alpha-spectrin linked anemia have decreased α-spectrin mRNA levels and diminished α-spectrin protein synthesis leading to abnormal, spectrin-deficient erythrocytes. (126) (127) (128) The precise genetic basis(es), i.e. the mutations on one or both alleles, of decreased spectrin mRNA accumulation in these cases is not known, even after mutation screening of the promoter and coding exons of the α-spectrin gene. Similarly, in congenital dyserythropoietic anemia type II (CDA II), a recessively inherited disorder due to mutations in the SEC23B gene, a number of patients exhibit all the phenotypic characteristics of CDA II, but a SEC23B mutation has only been identified on one allele. (129, 130) Both of these genes have candidate enhancers in the genomic vicinity, making these regions excellent candidates for disease-associated mutations in these patients. Gene expression and p300 and erythroid transcription factor occupancy in human primary erythroid cells. Gene expression levels were determined in primary human erythroid cell mRNA using Illumina microarrays. Expression levels of genes with p300 and erythroid transcription factor binding sites between 1-50kb of the transcription start site (white boxes) were compared to the expression levels of genes with binding sites >50kb (gray boxes). Combinations of the four erythroid transcription factors studied, any 2 of the 4, any 3 of the 4, and all 4, are shown. Table 4 , cloned upstream of a human gamma globin gene promoter-luciferase reporter gene cassette. These plasmids were transfected into human K562 cells as described. After two days, the cells were harvested and luciferase activity analyzed. Activity from test plasmids was normalized to that directed by the human gamma globin gene promoter-luciferase reporter gene control plasmid. Relative luciferase activity was expressed as that obtained from the test plasmids versus the activity obtained from the SV40 promoter-luciferase reporter gene plasmid pGL2P plasmid taking into account the transfection efficiency. The data are the means ± S.D. of at least six independent transfection experiments. The positive control plasmid contained the -globin gene HS2 enhancer cloned upstream of a -globin gene promoter-firefly luciferase reporter gene cassette. The negative control plasmid contained a promoterlessluciferase reporter gene cassette. *Conservation of human candidate enhancer regions was analyzed using the UCSC LiftOver tool at stringency levels of 75% or 50% of bases in the region that must remap. 
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